Compare IHT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IHT | NEUP |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.3M |
| IPO Year | N/A | N/A |
| Metric | IHT | NEUP |
|---|---|---|
| Price | $1.40 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 19.7K | ★ 112.7K |
| Earning Date | 12-19-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,463,789.00 | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.25 | $2.90 |
| 52 Week High | $4.24 | $21.40 |
| Indicator | IHT | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 39.33 |
| Support Level | $1.25 | $4.10 |
| Resistance Level | $1.49 | $4.65 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 65.47 | 50.91 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.